Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $54.2 million.

  • Axsome Therapeutics' Change in Accured Expenses rose 91910.58% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 14484.86%. This contributed to the annual value of $56.1 million for FY2024, which is 5380.5% up from last year.
  • Per Axsome Therapeutics' latest filing, its Change in Accured Expenses stood at $54.2 million for Q3 2025, which was up 91910.58% from $21.5 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Change in Accured Expenses registered a high of $54.2 million during Q3 2025, and its lowest value of -$8.4 million during Q1 2024.
  • For the 4-year period, Axsome Therapeutics' Change in Accured Expenses averaged around $14.2 million, with its median value being $11.4 million (2023).
  • As far as peak fluctuations go, Axsome Therapeutics' Change in Accured Expenses crashed by 21780.76% in 2024, and later surged by 91910.58% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Change in Accured Expenses (Quarter) stood at $13.2 million in 2022, then dropped by 13.91% to $11.4 million in 2023, then soared by 125.95% to $25.7 million in 2024, then skyrocketed by 111.32% to $54.2 million in 2025.
  • Its Change in Accured Expenses was $54.2 million in Q3 2025, compared to $21.5 million in Q2 2025 and $818000.0 in Q1 2025.